Noninvasive delivery systems for peptides and proteins in osteoporosis therapy: A retroperspective

Drug Development and Industrial Pharmacy

Volumn 36, Issue 1, 2010, Pages 31-44

  Hoyer, Herbert ^a   Perera, Glen ^a   Bernkop Schnürch, Andreas ^a  

^a UNIVERSITY OF INNSBRUCK   (Austria)

Author keywords

Calcitonin; Drug delivery; Mucoadhesive agent; Permeation enhancer; Teriparatide

Indexed keywords

ACYLCARNITINE; BILE SALT; CALCITONIN; CARBOMER; CHITOSAN; CYCLODEXTRIN DERIVATIVE; HYDROXYPROPYLMETHYLCELLULOSE; LIPOSOME; MICROSOMAL AMINOPEPTIDASE; MUCOLYTIC AGENT; N [8 (2 HYDROXY 4 METHOXY)BENZOYL]AMINO CYPRYLIC ACID; N ACETYLACETIC ACID; NANOCAPSULE; NONIONIC SURFACTANT; OVOMUCOID; PARATHYROID HORMONE; PARATHYROID HORMONE[1-34]; PENETRATION ENHANCING AGENT; POLY(N ISOPROPYLACRYLAMIDE); POLY(VINYLACETAMIDE); POLY(VINYLAMINE); POLYMER; POLYMETHACRYLIC ACID; PROTEINASE INHIBITOR; RECOMBINANT HUMAN INSULIN; SALCATONIN; SUCROSE COCOATE; TAUROCHOLIC ACID; TAURODEOXYCHOLIC ACID; TX 100; UNCLASSIFIED DRUG; UNINDEXED DRUG; WATER OIL CREAM;

BACKACHE; BONE REMODELING; CALCIUM BLOOD LEVEL; CALCIUM HOMEOSTASIS; CHEMICAL MODIFICATION; CLINICAL TRIAL; DIZZINESS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DEGRADATION; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM COMPARISON; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG METABOLISM; DRUG PENETRATION; ENCAPSULATION; ENZYMATIC DEGRADATION; EPISTASIS; EPISTAXIS; FLUSHING; FRACTURE; FRAGILITY FRACTURE; GASTROINTESTINAL ABSORPTION; HORMONE SUBSTITUTION; HUMAN; LEG CRAMP; MUCOADHESION; NAUSEA; NONHUMAN; OSTEOPOROSIS; PH; REVIEW; RHINORRHEA; SIDE EFFECT; TREATMENT DURATION; URINARY FREQUENCY;

ANIMALS; BONE DENSITY CONSERVATION AGENTS; BONE REMODELING; CALCITONIN; CALCIUM; DRUG DELIVERY SYSTEMS; EXCIPIENTS; HUMANS; OSTEOPOROSIS; PEPTIDES; PROTEINS; TERIPARATIDE;

EID: 74949108449     PISSN: 03639045     EISSN: 15205762     Source Type: Journal    
DOI: 10.3109/03639040903059342     Document Type: Review

References (108)

1. [No authors listed]. (1993). Consensus development conference on osteoporosis. Hong Kong, April 1-2, 1993. Am J Med, 95(5A):1S-78S.
2. Waller J, Angbratt M, Blomberg C, Kronhed AC, Larsson L, Löfman O, et al. (1997). Logics and logistics of community intervention against osteoporosis: An evidence basis. J Med Syst, 1:33-47.
3. Melton LJ. (1988). Osteoporosis: Etiology, diagnosis and management. In: Riggs BL, Melton LJ, eds. Epidemiology of fractures. New York: Raven Press, 133-154
4. Melton LJ 3rd, Thamer M, Ray NF, Chan JK, Chesnut CH III, Einhorn TA, et al. (1997). Fractures attributable to osteoporosis: Report from the National Osteoporosis Foundation. J Bone Miner Res, 12(1):16-23.
5. Häussler B, Gothe H, Göl D, Glaeske G, Pientka L, Felsenberg D. (2007). Epidemiology, treatment and costs of osteoporosis in Germany-the BoneEVA study. Osteoporos Int, 18:77-84.
6. Trombetti A, Herrmann F, Hoffmeyer P, Schurch MA, Bonjour JP, Rizzoli R. (2002). Survival and potential years of life lost after hip fracture in men and age-matched women. Osteoporos Int, 13(9):731-737
7. Khan A. (2003). Advances in osteoporosis therapy. 2003 update of practical guidelines. Can Fam Physician, 49:441-447
8. Fleisch H. (1994). Bisphosphonates in osteoporosis. Br J Clin Pract, 48:323-326
9. Mitlak BH, Cohen FJ. (1999). Selective estrogen receptor modulators: A look ahead. Drugs 57:653-663
10. Writing Group for the Women's Health Initiative investigators. (2002). Risks and benefits of estrogen plus progestin in healthy postmenopausal women-principal results from the Women's Health Initiative randomized controlled trial. JAMA, 288:321-333
11. Cholewinski M, Luckel B, Horn H. (1996). Degradation pathways. Analytical analyzation and formulation strategies of a peptide and protein calcitonin and human growth hormone in comparison. Pharm Acta Helv, 71:405-419
12. Potts JR. (1992). Chemistry of calcitonins. Bone Miner, 16:169-173
13. Torres-Lugo M, Peppas NA. (2000). Transmucosal delivery systems for calcitonin: A review. Biomaterials, 21:1191-1196
14. Reginster JY, Deroisy R, Lecart MP, Sarlet N, Zegels B, Jupsin I. (1995). A double-blind, placebo-controlled, dose-finding trial of intermittent nasal salmon calcitonin for prevention of postmenopausal lumbar spine bone loss. Am J Med, 98:452-458
15. Prestwood KM, Pilbeam CC, Raisz LG. (1995). Treatment of osteoporosis. Annu Rev Med, 46:249-256
16. Patlas N, Golomb G, Yaffe P, Pinto T, Breuer E, Ornoy A. (1999). Transplacental effects of bisphosphonates on fetal skeletal ossification and mineralization in rats. Teratology, 60(2):68-73.
17. Graepel P, Bentley P, Fritz H, Miyamoto M, Slater SR. (1992). Reproduction toxicity studies with pamidronate. Arzneimittelforschung, 42(5):654-667
18. Werle M, Samhaber A, Bernkop-Schnürch A. (2006). Degradation of teriparatide by gastro-intestinal proteolytic enzymes. J Drug Target, 14(3):109-115
19. Morley P. (2005). Delivery of parathyroid hormone for the treatment of osteoporosis. Expert Opin Drug Deliv, 2(6):993-1002.
20. Reeve J, Mitchell A, Tellez M. (2001). Treatment with parathyroid peptides and estrogen replacement for severe postmenopausal vertebral osteoporosis: Prediction of long-term response in spine and femur. J Bone Miner Metab, 19:102-114
21. Freeman TR. (2003). Teriparatide: A novel agent that builds new bone. J Am Pharm Assoc, 43(4):535-537
22. Macheras P, Reppas C, Dressman JB., eds. (1995). Biopharmaceutics of orally administered drugs. In: Pharmaceutical technology, 1st ed. London: Ellis Harwood, 1-2.
23. Mize NK, Buttery M, Ruis N, Leung I, Cormier M, Daddona P. (1997). Antiflammin 1 peptide delivered non-invasively by iontophoresis reduces irritant-induced inflammation in vivo. Exp Dermatol, 6(4):181-185
24. Mitragotri S, Blankschtein D, Langer R. (1995). Ultrasoundmediated transdermal protein delivery. Science, 269:850-853
25. Niven RW. (1995). Delivery of biotherapeutics by inhalation aerosol. Crit Rev Ther Drug Carrier Syst, 12(2-3):151-231.
26. Adjei AL, Gupta PK. (1997). Lung biology in health and disease: Inhalation delivery of therapeutic peptides and proteins, vol.107. New York: Marcel Dekker.
27. Sinko PJ, Lee YH, Makhey V, Leesman GD, Sutyak JP, Yu H, et al. (1999). Biopharmaceutical approaches for developing and assessing oral peptide delivery strategies and systems: In vitro permeability and in vivo oral absorption of salmon calcitonin (sCT). Pharm Res, 16(4):527-534
28. Leone-Bay A, Sato M, Paton D, Hunt AH, Sarubbi D, Carozza M, et al. (2001). Oral delivery of biologically active parathyroid hormone. Pharm Res, 18(7):964-970
29. Mackay M. (1991). Delivery of recombinant peptide and protein drugs. Biotechnol Genet Eng Rev, 8:251-278
30. Luise MD, Martin TJ, Greenberg PB, Michelangeli V. (1972). Metabolism of porcine, human and salmon calcitonin in the rat. J Endocrinol, 53:475-482
31. Marschütz MK, Caliceti P, Bernkop-Schnürch A. (2000). Design and in vivo evaluation of an oral delivery system for insulin. Pharm Res, 17(12):1468-1474
32. Lee YH, Sinko PJ. (2000). Oral delivery of salmon calcitonin. Adv Drug Deliv Rev, 42:225-238
33. Shen WC. (2003). Oral peptide and protein delivery: Unfulfilled promises? Drug Discov Today, 8(14):607-608
34. Aungst BJ. (2000) Intestinal permeation enhancers. J Pharm Sci, 89:429-442
35. Dohi M, Nishibe Y, Makino Y, Suzuki Y. (1993). Enzymatic barrier to nasal delivery of salmon calcitonin in rabbits. In: Proceedings of the international symposium control on release society, Kyoto, Japan, p. 9.
36. Guggi D, Bernkop-Schnürch A. (2003). In vitro evaluation of polymeric excipients protecting calcitonin against degradation by intestinal serine proteases. Int J Pharm, 252:187-196
37. Shah RB, Khan MA. (2003). Protection of salmon calcitonin breakdown with serine proteases by various ovomucoid species for oral drug delivery. J Pharm Sci, 93(2):392-406.
38. Lee YH, Perry BA, Labruno S, Lee HS, Stern W, Falzone LM, et al. (1999). Impact of regional intestinal pH modulation on absorption of peptide drugs: Oral absorption studies of salmon calcitonin in beagles. Pharm Res, 16:1233-1239
39. Legg EF, Spencer AM. (1975). Studies on the stability of pancreatic enzymes in duodenal fluid to storage temperature and pH. Clin Chim Acta, 65:175-179
40. Takatsuka S, Morita T, Koguchi A, Horikiri Y, Yamahara H, Yoshino H. (2006). Synergistic absorption enhancement of salmon calcitonin and reversible mucosal injury by applying a mucolytic agent and a non-ionic surfactant. Int J Pharm, 316:124-130
41. Leone-Bay A, Sato M, Paton D, Hunt AH, Sarubbi D, Carozza M, et al. (2001). Oral delivery of biological active parathyroid hormone. Pharm Res, 18(7):964-970
42. Ogiso T, Funahashi N, Tsukioka Y, Iwaki M, Tanino T, Wada T. (2001). Oral delivery of synthetic eel calcitonin, elcatonin in rats. Biol Pharm Bull, 24(6):656-661
43. Swenson ES, Curalo W. (1992). Intestinal permeability enhancement for proteins, peptides, and other polar drugs: mechanisms, and potential toxicity. Adv Drug Deliv Rev, 8:39-92.
44. Sakai M, Imai T, Ohtake H, Otagiri M. (1998). Cytotoxicity of absorption enhancers in Caco-2 cell monolayers. J Pharm Pharmacol, 50:1101-1108
45. Yamamoto A, Uchiyama T, Nishikawa R, Fujita T, Muranishi S. (1996). Effectiveness and toxicity screening of various absorption enhancers in the rat small intestine: Effects of absorption enhancers on the intestinal absorption of phenol red and the release of protein and phospholipids from the intestinal membrane. J Pharm Pharmacol, 48:1285-1289
46. Bernkop-Schnürch A, Kast CE. (2001). Chemically modified chitosans as enzyme inhibitors. Adv Drug Deliv Rev, 52:127-137
47. Bernkop-Schnürch A. (2000). Chitosan and its derivates: Potential excipients for peroral peptide delivery systems. Int J Pharm, 194:1-13.
48. Bernkop-Schnürch A. (2005). Thiomers: A new generation of mucoadhesive polymers. Adv Drug Deliv Rev, 57:1569-1582 (Pubitemid 41443470)
49. Kafedjiiski K, Föger F, Werle M, Bernkop-Schnürch A. (2005). Synthesis and in vitro evaluation of a novel chitosan-glutathione conjugate. Pharm Res, 22:1480-1488 (Pubitemid 41215888)
50. Kafedjiiski K, Werle M, Föger F, Bernkop-Schnürch A. (2005). Synthesis and in vitro characterization of a novel poly(acrylic acid)-glutathione conjugate. J Drug Deliv Sci Technol, 15(6):411-417 (Pubitemid 41695888)
51. Bernkop-Schnürch A, Schwarz V, Steininger S. (1999). Polymers with thiol groups: A new generation of mucoadhesive polymers? Pharm Res, 16:876-881 (Pubitemid 29284199)
52. Kast CE, Guggi D, Langoth N, Bernkop-Schnürch A. (2003). Development and in vivo evaluation of an oral delivery system for low molecular weight heparin based on thiolated polycarbophil. Pharm Res, 20(6):931-936
53. Thaler SC, Bernkop-Schnürch A. (1999). Polycarbophil-cysteine conjugates as platforms for oral polypeptide delivery systems. J Pharm Sci, 89:901-909
54. Guggi D, Krauland A, Bernkop-Schnürch A. (2003). Systemic peptide delivery via the stomach: In vivo evaluation of an oral storage form for salmon calcitonin. J Control Release, 92:125-135
55. Guggi D, Kast CE, Bernkop-Schnürch A. (2003). In vivo evaluation of a salmon calcitonin-delivery system based on a thiolated chitosan carrier matrix. Pharm Res, 20(12):1989-1994
56. Bernkop-Schnürch A, Kast CE, Guggi D. (2003). Permeation enhancing polymers in oral delivery of hydrophilic macromolecules: Thiomer/GSH systems. J Control Release, 93:95-103.
57. Müller RH, Hildebrand GE. (2003). Pharmazeutische technologie: Moderne arzneiformen, 2nd ed. Stuttgart: Wissenschaftliche Verlagsgesellschaft.
58. Ousorren C, Storm G, Crommelin DJA, Senior JH. (2000). Liposomes for local sustained drug release. In: Senior JH, Radomsky M, eds. Sustained-release injectable products. Denver: Interpharm Press, 137-180
59. Song KH, Chung SJ, Shim CK. (2005). Enhanced intestinal absorption of salmon calcitonin (sCT) from proliposomes containing bile salts. J Control Release, 106:298-308.
60. Thirawong N, Thongborisute J, Takeuchi H, Sriamornsak P. (2008). Improved intestinal absorption of calcitonin by mucoadhesive delivery of novel pectin-liposome nanocomplexes. J Control Release, 125:236-245
61. Takeuchi H, Matsui Y, Yamamoto H, Kawashima Y. (2003). Mucoadhesive properties of carbopol and chitosan-coated liposomes and their effectiveness in the oral administration of calcitonin to rats. J Control Release, 86:235-242
62. Lamprecht A, Yamamoto Y, Takeuchi H, Kawashima Y. (2004). pH sensitive microsphere delivery increases oral bioavailability of calcitonin. J Control Release, 98:1-8.
63. Almeida AJ, Souto E. (2007). Solid lipid nanoparticles as a drug delivery systems for peptides and proteins. Adv Drug Deliv Rev, 59:478-490 (Pubitemid 47260710)
64. Garcia-Fuentes M, Torres D, Alonso MJ. (2005). New-surface modified lipid nanoparticles as delivery vehicles for salmon calcitonin. Int J Pharm, 296:122-132
65. Garcia-Fuentes M, Prego C, Torres D, Alonso MJ. (2005). A comparative study of the potential of solid triglyceride nanostructures coated with chitosan or poly(ethylene glycol) as carriers for oral calcitonin delivery. Eur J Pharm Sci, 25:133-143
66. Sakuma S, Suzuki N, Sudo R, Hiwatari K, Arikawa K, Kishida A, et al. (2002). Optimized chemical structure of nanoparticles as carriers for oral delivery of salmon calcitonin. Int J Pharm, 239:185-195
67. Sakuma S, Suzuki N, Kikuchi H, Hiwatari K, Arikawa K, Kishida A, et al. (1997). Oral peptide delivery using nanoparticles composed of novel graft copolymers having hydrophobic backbone and hydrophilic branches. Int J Pharm, 149:93-106.
68. Sakuma S, Suzuki N, Kikuchi H, Hiwatari K, Arikawa K, Kishida A, et al. (1997). Absorption enhancement of orally administered salmon calcitonin by polystyrene nanoparticles having poly(N-isopropylacrylamide) branches on their surfaces. Int J Pharm, 158:69-78.
69. Sakuma S, Hayashi M, Akashi M. (2001). Design of nanoparticles composed of graft copolymers for oral peptide delivery. Adv Drug Deliv Rev, 47:21-37.
70. Sakuma S, Ishida Y, Sudo R, Suzuki N, Kikuchi H, Hiwatari K, et al. (1997). Stabilization of salmon calcitonin by polystyrene nanoparticles having surface hydrophilic polymeric chains, against enzymatic degradation. Int J Pharm, 159:181-189
71. Yoo HS, Park TG. (2004). Biodegradable nanoparticles containing protein-fatty acid complexes for oral delivery of salmon calcitonin. J Pharm Sci, 93(2):488-495
72. Prego C, Fabre M, Torres D, Alonso MJ. (2006). Efficacy and mechanism of action of chitosan nanocapsules for oral peptide delivery. Pharm Res, 23(3):549-556
73. Prego C, Torres D, Fernandez-Megia E, Novoa-Carballal R, Quinoa E, Alonso MJ. (2006). Chitosan-PEG nanocapsules as new carriers for oral peptide delivery. Effect of chitosan pegylation degree. J Control Release, 111:299-308.
74. Bernkop-Schnürch A, Heinrich A, Greimel A. (2006). Development of a novel method for the preparation of submicron particles based on thiolated chitosan. Eur J Pharm Biopharm, 63(2):166-172
75. Bernkop-Schnürch A, Weithaler A, Albrecht K, Greimel A. (2006). Thiomers: Preparation and in vitro evaluation of a mucoadhesive nanoparticulate drug delivery system. Int J Pharm, 317:76-81. (Pubitemid 43866341)
76. Deutel B, Greindl M, Thaurer M, Bernkop-Schnürch A. (2008). Novel insulin thiomer nanoparticles: In vivo evaluation of an oral drug delivery system. Biomacromolecules, 9: 278-285
77. Baluom M, Friedman DI, Rubinstein A. (1997). Absorption enhancement of calcitonin in the rat intestine by carbopolcontaining submicron emulsions. Int J Pharm, 154:235-243
78. Bai JPF, Chang LL, Guo JH. (1995). Effects of polyacrylic polymers on the luminal proteolysis of peptide drugs in the colon. J Pharm Sci, 84(11):1291-1294
79. MacFarlane GT, Cummings JH, Allison CJ. (1986). Protein degradation by human intestinal bacteria. J Gen Microbiol, 132:1647-1656
80. Wang J, Shen D, Shen WC. (1999). Preparation, purification, and characterization of a reversible lipidized desmopressin with potentiated anti-diuretic activity. Pharm Res, 16:1674-1679
81. Wang J, Chow D, Heiati H, Shen WC. (2003). Reversible lipidization for the oral delivery of salmon calcitonin. J Control Release, 88:369-380
82. Miacalcin® Nasal Spray. (1998). Novartis Pharmaceutical Corp. East Hanover, NJ.
83. Agu R, Valiveti S, Earles DC, Klausner M, Hayden PJ, Wermeling DP, et al. (2004). Intranasal delivery of recombinant human parathyroid hormone [hPTH (1-34)], teriparatide in rats. Endocr Res, 30(3):455-467
84. Illum L. (2003). Nasal drug delivery-possibilities, problems and solutions. J Control Release, 87(1-3):187-198
85. Gizurarson S, Bechgaard E. (1991). Study of nasal enzyme activity towards insulin. In vitro. Chem Pharm Bull, 39(8):2155-2157
86. Lee WA, Ennis RD, Longenecker JP, Bengtsson P. (1994). The bioavailability of intranasal salmon calcitonin in healthy volunteers with and without a permeation enhancer. Pharm Res, 11(5):747-750
87. Pontiroli AE, Alberetto M, Calderara A, Pajetta E, Pozza G. (1989). Nasal administration of glucagon and human calcitonin to healthy subjects: A comparison of powders and spray solutions and of different enhancing agents. Eur J Clin Pharmacol, 37(4):427-430
88. Kagatani S, Shinoda T, Fukui M, Ohmura T, Hasumi S, Sonobe T. (1996). Enhancement of nasal salmon calcitonin absorption by lauroylcarnitine chloride in rats. Pharm Res, 13(5):739-743
89. Schipper NG, Verhoef JC, Romeijn SG, Merkus FW. (1995). Methylated β-cyclodextrins are able to improve the nasal absorption of salmon calcitonin. Calcif Tissue Int, 56(4):739-743
90. Sinswat P, Tengamnuay P. (2003). Enhancing effect of chitosan on nasal absorption of salmon calcitonin in rats: Comparison with hydroxypropyl- and dimethyl-β-cyclodextrins. Int J Pharm, 257(1-2):12-22.
91. Ahsan F, Arnold J, Meezan E, Pillion DJ. (2001). Enhanced bioavailability of calcitonin formulated with alkylglycosides following nasal and ocular administration in rats. Pharm Res, 18(12):1742-1746
92. Ahsan F, Arnold J, Meezan E, Pillion DJ. (2003). Sucrose cocoate, component of cosmetic preparations, enhances nasal and ocular peptide absorption. Int J Pharm, 251(1-2): 195-203.
93. Matsuyama T, Morita T, Horikiri Y, Yamahara H, Yoshino H. (2006). Enhancement of nasal absorption of large molecular weight compounds by combination of mucolytic agent and nonionic surfactant. J Control Release, 110(2):347-352
94. Schipper NG, Romeijn SG, Verhoef JC, Merkus FW. (1993). Nasal insulin delivery with dimethyl-β-cyclodextrin as an absorption enhancer in rabbits: Powder more effective than liquid formulations. Pharm Res, 10(5):682-686
95. Ishikawa F, Katsura M, Tamai I, Tsuji A. (2001). Improved nasal bioavailability of elcatonin by insoluble formulation. Int J Pharm, 224(1-2):105-114
96. Matsuyama T, Morita T, Horikiri Y, Yamahara H, Yoshino H. (2006). Improved nasal absorption of salmon calcitonin by powdery formulation with N-acetyl-L-cysteine as a mucolytic agent. Pharm Res, 115(2):183-188
97. Matsuyama T, Morita T, Horikiri Y, Yamahara H, Yoshino H. (2006). Influence of fillers in powder formulations containing N-acetyl-L-cysteine on nasal peptide absorption. Pharm Res, 120(1-2):88-94.
98. Morimoto K, Katsumata H, Yabuta T, Iwanaga K, Kakemi M, Tabata Y, et al. (2001). Evaluation of gelatin microspheres for nasal and intramuscular administrations of salmon calcitonin. Eur J Pharm Sci, 13(2):179-185
99. Byron PR, Patton JS. (1994). Drug delivery via the respiratory tract. J Aerosol Med, 7(1):49-75.
100. Patton JS, Byron PR. (2007). Inhaling medicines: Delivering drugs to the body through the lungs. Nat Rev Drug Discov, 6(1):67-74.
101. Kobayashi S, Kondo S, Juni K. (1994). Study on pulmonary delivery of salmon calcitonin in rats: Effects of protease inhibitors and absorption enhancers. Pharm Res, 11(9):1239-1243
102. Kobayashi S, Kondo S, Juni K. (1994). Pulmonary delivery of salmon calcitonin dry powders containing absorption enhancers in rats. Pharm Res, 13(1):80-83
103. Yamamoto H, Kuno Y, Sugimoto S, Takeuchi H, Kawashima Y. (2005). Surface-modified PLGA nanosphere with chitosan improved pulmonary delivery of calcitonin by mucoadhesion and opening of intercellular tight junctions. J Control Release, 102(2):373-381
104. Patton JS, Trinchero P, Platz RM. (1995). Bioavailability of pulmonary delivered peptides and proteins: ?-interferon, calcitonin and parathyroid hormones. J Control Release, 102(2):373-381
105. Codrons V, Vanderbrist F, Verbeeck RK, Arras M, Lison D, Preat V, et al. (2003). Systemic delivery of parathyroid hormone (1- 34) using inhalation dry powders in rats. J Pharm Sci, 92(5):938-950
106. Alur HH, Beals JD, Pather SI, Mitra AK, Johnston TP. (1999). Evaluation of a novel, natural oligosaccharide gum as a sustained- release and mucoadhesive component of calcitonin buccal tablets. J Pharm Sci, 88(12):1313-1319
107. Cui Z, Mumper RJ. (2002). Buccal transmucosal delivery of calcitonin in rabbits using thin-film composites. Pharm Res, 19(12):1901-1906
108. Galindo-Rodriguez SA, Allemann E, Fessi H, Doelker E. (2005). Polymeric nanoparticles for oral delivery of drugs and vaccines: A critical evaluation of in vivo studies. Crit Rev Ther Drug Carrier Syst, 22:419-464